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Background: Extracorporeal photopheresis (ECP), an apheresis-based therapy
for various immunological diseases, works mainly by inducing apoptosis in
lymphocytes. Several factors influence the efficacy of ECP with the photosensi-
tizer 8-methoxypsoralen (8-MOP) and ultraviolet light A (UVA). This study
aimed to optimize treatment by varying the 8-MOP starting concentration and
the cell suspension medium.
Materials and Methods: All patients (n = 13) included in this study
received photopheresis as medically indicated. Cells collected with a Spec-
tra Optia apheresis system were suspended in plasma or physiological
saline (NaCl) and incubated with 200 ng/ml versus 340 ng/ml photosensi-
tizer before UVA irradiation (Macogenic G2 or UVA PIT system). Lympho-
cyte apoptosis and caspase activity were analyzed by flow cytometry and
fluorimetry, and residual 8-methoxypsoralen concentrations by liquid
chromatography–mass spectrometry.
Results: Raising the 8-MOP starting concentration significantly increased lym-
phocyte apoptosis, with values of 22% versus 35% (plasma) and 28%–46%
(NaCl) at 24 h post-ECP and 37% versus 86% (plasma) and 74% versus 97%
(NaCl) at 48 h for 200 ng/ml versus 340 ng/ml. Pre-transfusion residual
8-MOP levels were 168 ng/ml (plasma) and 162 ng/ml (NaCl) versus
290 ng/ml (plasma) and 266 ng/ml (NaCl) for the lower versus higher dose,
respectively.
Discussion: Hence, 8-MOP concentration influences the efficacy of photo-
pheresis as lymphocyte apoptosis rates were significantly higher with the
higher starting concentration and with NaCl versus plasma. This indicates that
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increased 8-MOP starting doses and saline as additional suspension medium
could help in improving ECP's efficacy.
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1 | INTRODUCTION
Extracorporeal photopheresis (ECP) is an immunomodula-
tory therapy for T-cell mediated diseases such as cutaneous
T-cell lymphoma, graft-versus-host-disease (GvHD), and
solid organ transplant rejection.1–4 In ECP, autologous
leukapheresis is performed with subsequent ultraviolet A
(UVA) irradiation in the presence of the photoactive sub-
stance 8-methoxypsoralen (8-MOP). This leads to transcrip-
tion and replication inhibition followed by cell inactivation
and apoptosis.5–8
The immunological mechanisms, although not com-
pletely understood, are mainly lymphocyte apoptosis,9, 10
the initiation of dendritic cells (DC), and a rapid clearance
of apoptotic cells.11 Following ECP, the cytokine profile is
modified toward upregulation of immunosuppressive fac-
tors and down regulation of co-stimulatory molecules.12
Furthermore, antigen-presenting cells (APC) suppress T-cell
effector activity and support regulatory T-cell (Treg)
function.13, 14
Apoptosis induction is a central mechanism of
ECP,4, 15–19 and several factors influence the efficacy of
8-MOP/UVA treatment (see Figure 1). In general, the two
standard starting concentrations of 8-MOP used for photo-
pheresis are 200 ng/ml for offline ECP, and 340 ng/ml for
inline ECP (calculated as product volume  0.017
according to the instruction for use of Uvadex, Therakos).
The cell suspension matrix (plasma vs. saline) also
influences the effect of 8-MOP in solution.20 Plasma has
two contradictory consequences for 8-MOP/UVA: it com-
promises 8-MOP availability for cellular uptake due to
plasma protein binding on the one hand,6, 21 but mini-
mizes 8-MOP adhesion and absorbance to plastic mate-
rials on the other. 8-MOP is known for its affinity to
various plastic materials, especially the polyvinylchloride
used to make medical tubing and blood bags. UVA irradi-
ation bags usually consist of ethylene-vinyl acetate, to
which 8-MOP adheres to a lesser degree. Saline solution
(NaCl), on the other hand, facilitates 8-MOP adhesion to
bag surfaces.22
The efficacy of 8-MOP/UVA may possibly be influenced
by the incubation time between addition of the photosensi-
tizer and UVA irradiation. This substance diffuses within
minutes into the cells.23 Equilibrium within the cell suspen-
sion, however, may take up to 30 min.24
Treatment efficacy is further influenced by the UVA
dose, which directly influences T-cell apoptosis.20 A dose
of 1–2 J/cm2 is widely used at a range of wavelength of
320–400 nm.6, 25 The efficacy of irradiation also depends
on the hematocrit (HCT) of the product; it is com-
promised at HCT levels of more than 4% because RBCs
intercept UV light.20, 26
The aim of this study was to optimize 8-MOP/UVA
by modulating the 8-MOP concentration and the cell sus-
pension matrix.
2 | MATERIAL AND METHODS
2.1 | Patients
Data were obtained from 2018 to 2020 according to the
EU Guidelines for Good Manufacturing Practice.27 All
participants gave their informed consent and received
ECP as medically indicated.28 The study included a total
of 13 patients (11 male, 2 female), 5 with GvHD, 3 with
cutaneous T-cell lymphoma, and 5 with cellular solid
organ transplant rejection. The study protocol was
approved by the local ethics committee of the University
Hospital Regensburg (16-101-0046).
FIGURE 1 Critical parameters influencing the efficacy of
photopheresis. Shown are several factors that influence binding of
the photosensitizer 8-methoxypsoralen to DNA [Color figure can be
viewed at wileyonlinelibrary.com]
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2.2 | Photopheresis
All ECP procedures (n = 42) were carried out with aphe-
resis and UVA irradiation on separate devices (offline
ECP). UV irradiation was performed either with the
Macogenic G2 (Macopharma, France; n = 14) or
the UVA PIT system (PIT Medical Systems GmbH,
Germany; n = 28). Mononuclear cell (MNC) suspensions
were obtained with a Spectra Optia (Terumo BCT, Lake-
wood, CO) apheresis system in the continuous mononu-
clear cell collection (CMNC) mode. The ECP procedures
were set up to yield leukocyte and plasma volumes of
90 and 110 ml (UVA PIT) or 90 and 210 ml (Macogenic
G2), respectively, after cell harvesting. Each resulting cell
suspension was sterilely transferred to the irradiation sys-
tem and 8-methoxypsoralen (8-MOP, Uvadex, Therakos,
West Chester, PA) was injected into the bag at a concentra-
tion of 20 mg/l to yield a starting concentration of
200 ng/ml (low-dose) or 340 ng/ml (high-dose), respec-
tively, of the drug. Patients were assigned to a high or low-
dose 8-MOP starting concentration with MNCs suspended
in plasma or saline, respectively, whereby high-dose 8-MOP
was always delivered with UVA PIT system. After incuba-
tion with the photosensitizer, a UVA dose of 2 J/cm2 was
delivered with UVA PIT or Macogenic G2, as indicated,
and the resultant cell suspension (product after sampling)
was immediately infused to the patient (see Figure 2).
2.3 | Sample preparation
ECP product samples were taken before the addition of
8-methoxypsoralen (pre) and after UVA irradiation
(post). Apoptosis and caspase-3/7 testing was carried out
from pre- and post-samples immediately after sampling
(0 h), and after 24 and 48 h incubation in TexMACS
GMP medium (Miltenyi, Bergisch-Gladbach, Germany)
with 1% Glutamax (Gibco) at 37°C and 5% CO2.
2.4 | Analytics
2.4.1 | Flow cytometry
Briefly, 1  106 MNCs/tube were stained after treatment
with FcR Blocking Reagent (Miltenyi). Immuno-
phenotyping of leukocytes was performed with commer-
cially available antibodies from Beckman Coulter
(BC): CD45-KrOrange, CD3-ECD, CD56-APC-AF750,
CD20-APC-AF750, CD19-APC-AF750, and CD66b-APC-
AF750. The BC Annexin V/7-AAD kit was used for apo-
ptosis detection. All antibodies were titrated to obtain
an optimal concentration.
Flow cytometric analyses were performed with the
Navios Ex and Navios flow cytometers, Cytometry List
Mode Data Acquisition Software, version 2.0 and 1.3,
respectively, and Kaluza Analysis Software from Beckman
Coulter, version 2.1. T-cells (CD3) were analyzed by exclud-
ing granulocytes (CD66b), natural killer (NK) cells (CD56),
and B cells (CD19, CD20). Annexin V+ and 7-AAD+/ cells
were sub-gated from T-cells. Apoptosis induction levels
were calculated as the percentage ratio of post/pre
photopheresis.29
2.4.2 | Caspase 3/7 activity assay
Caspase activity was measured in ECP samples obtained
with Optia and UVA PIT using the Cell Meter Fluorimetric
Caspase 3/7 activity kit (AAT Bioquest, Sunnyvale, CA)
according to manufacturer's instructions. In brief, 40,000
mononuclear cells per group were seeded in duplicates in
96-well plates (seeding volume: 100 μl). Exactly 24 and 48 h
after ECP with Optia and UVA PIT, fluorogenic caspase-
3/-7 substrate (DEVD)2-R110 was added (volume: 70 μl),
and the plates were incubated for 90 min at room tempera-
ture in the dark. Subsequently, light emission was quanti-
fied using a Victor3 Multilabel Reader (Perkin Elmer, MA).
ECP-related caspase-3 and 7 activity was calculated and
expressed as relative fluorescence units (RFU) in the post-
ECP sample minus that in the pre-ECP sample.
2.4.3 | 8-MOP HPLC–MS/MS
The photopheresis supernatant (pre and post) was ana-
lyzed by liquid chromatography/mass spectrometry
(LC–MS/MS) using the Agilent Technologies 1200 Series
(Santa Clara, CA) and Varian 320-MS systems, if
FIGURE 2 Flow chart of extracorporeal photopheresis
procedure and sampling. “Pre” and “post” samples were analyzed
for residual 8-MOP and incubated up to 48 h for caspase and
apoptosis analysis
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indicated, or the Agilent Technologies 1290 Infinity and
6495 TQ Mass Spectrometer systems as already
published.30
2.4.4 | Cell count
Cell concentrations and hematocrit were measured
undiluted on an XN-550 Automated Hematology Analyzer
(Sysmex, Kobe, Japan) per manufacturer's instructions.
2.5 | Statistical analysis
Data were analyzed and figures generated using Micro-
soft Excel 2010 and IBM SPSS Statistics 25 software.
Descriptive statistics included absolute numbers, frequen-
cies, ratios, means with standard deviations, and medians
with interquartile ranges. Correlations were determined
with Pearson correlation coefficient. p values below 0.05
were considered statistically significant. Normal distribu-
tion was analyzed by the Anderson–Darling test from R's
package nortest.
3 | RESULTS
ECP was performed with cell separation and UVA irradi-
ation on separate devices. The study included 13 patients
with different diagnoses requiring ECP therapy. The cell
suspension volumes varied depending on the irradiation
system between 200 ml (UVA PIT) and 300 ml
(Macogenic G2). The cellular composition of the ECP
products was also variable and depended on the composi-
tion of cells in the peripheral blood of the individual
patient (see Table 1). The products had a hematocrit of
0.5%–1.9%, which was in line with previously published
values by Spectra Optia.31 In general, a UVA dose of
2 J/cm2 was delivered with both systems. The UVA PIT
adjusted the exposure time according to the individual
product volume and hematocrit to yield the defined UVA
dose. Thus, the irradiance of UVA, in Joules, correlated
with the hematocrit of the product (R2 = 0.9924).
Apoptosis of CD3+ T-cells, a well-known mechanism
induced by ECP, was detected as soon as after 24 h incu-
bation, as determined by discriminating between living,
apoptotic (Annexin V+), and necrotic (7-AAD+) T-cells.
Cells were suspended in plasma and irradiated with UVA
PIT or Macogenic G2. Samples were taken before addi-
tion of 200 ng/ml 8-MOP and after irradiation to measure
apoptosis without (pre) and with ECP treatment (post)
and to calculate apoptosis induction (percentage ratio of
post/pre) up to 48 h after ECP (n = 24; see Figure 3).
After in vitro cultivation of the cells, 22% (3% to 114%)
of CD3+ T-cells were apoptotic at 24 h compared with
37% (3%–86%) at 48 h. Tests for the association between
cell content and apoptosis rates revealed no correlation
between the proportions of leukocytes (p = 0.497), lym-
phocytes (p = 0.260), monocytes (p = 0.169), or neutro-
phils (p = 0.168) in the products and T-cell apoptosis
rates 48 h after treatment.
Apoptosis is a regulated cell death process leading to
the activation of proteolytic enzymes (caspases 3, 6, 7),
DNA fragmentation, and chromatin condensation.32
Therefore, caspase 3 and 7 activity was detected at ECP
with the Spectra Optia and UVA PIT system with the
standard conditions of 200 ng/ml 8-MOP and plasma, to
verify apoptosis due to the ECP procedure (n = 12).
Caspase activity increased from 29 RFU (median;
range: 299–522 RFU) at 0 h to 8923 RFU (median; range:
133–20,869 RFU) at 24 h and 13,092 RFU (median;
range: 1589–75,118 RFU) at 48 h; these levels assured
advanced initiation of apoptosis already after 24 h (see
Figure 4).
Comparison of the two UVA irradiation systems
with 200 ng/ml 8-MOP and plasma revealed T-cell
apoptosis induction rates by flow cytometry of
0%–35% (median 21%, n = 12) with UVA PIT versus
14%–114% (median 28.5%, n = 12) with Macogenic
G2 24 h after treatment. At 48 h, the rates were
11%–86% (median 37.5%) and 3%–60% (median
TABLE 1 Patient and ECP product characteristics
Patient characteristics
Age 57 years (34–65)
Sex 11 male, 2 female
Diagnosis Graft versus host disease
(n = 5), T-cell lymphoma
(n = 3), solid organ
transplant rejection (n = 5)
Leukocytes, peripheral 3.8  103/μl (1.7–11.5  103/μl)
Lymphocytes, peripheral 11% (2.1%–55%)
Platelets, peripheral 196  103/μl (16–387  103/μl)
ECP product characteristics
Product volume 234 ml (178–282 ml)
Leukocytes 16.5  103/μl (4.7–67.1  103/μl)
34  108 (13–133  108)
Lymphocytes 32% (11%–73%)
Platelets 1.5  1011 (0.2–3.5  1011)
Hematocrit 1.2% (0.5%–1.9%)
Note: Characteristics of the study population and extracorporeal
photopheresis (ECP) products. Data are presented as median and range.
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24.5%), respectively. There was no significant differ-
ence in apoptosis induction between the two UVA
systems (p = 0.164).
Our standard ECP procedure specifies a UVA irradia-
tion dose of 2 J/cm2 with an 8-MOP starting dose of
200 ng/ml. With the aim of optimizing the ECP
FIGURE 3 T-cell apoptosis induced by photopheresis. Extracorporeal photopheresis product samples were analyzed before versus
24 and 48 h after treatment with 8-MOP and ultraviolet light A irradiation. Necrotic and apoptotic T-cells were discriminated from live
T-cells by Annexin V and 7-AAD staining [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 4 Increases in
caspase 3 and 7 activity 24 and
48 h after extracorporeal
photopheresis (ECP). Post–pre
caspase-3/-7 activity levels were
calculated by subtracting the




24 and 48 h after irradiation
(post) with the Optia and
ultraviolet light A PIT system,
respectively, from those detected
before treatment (pre) and
expressed in relative
fluorescence units (RFU).
Outliers are marked as asterisks
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procedure, we analyzed different combinations of 8-MOP
starting doses (200 or 340 ng/ml) and cell suspension
matrices (plasma or saline) (see Figure 5). With the lower
8-MOP starting concentration (200 ng/ml), apoptosis
induction rates in plasma and saline as determined by
flow cytometry were 22% and 28% after 24 h and 37% and
74% after 48 h, respectively. The use of an 8-MOP con-
centration of 340 ng/ml according to inline ECP stan-
dards (volume product  0.017) increased apoptosis
induction levels after 24 h (35% in plasma and 46% in
NaCl) compared with the standard dose, and the increase
observed in the saline group at 24 h was statistically sig-
nificant (p = 0.044). After 48 h, apoptosis induction by
340 ng/ml 8-MOP was even higher: 86% (plasma) and
97% (NaCl). For NaCl, the difference between the two
doses at 48 h was significant (p = 0.02). The level of apo-
ptosis induction with high-dose 8-MOP (340 ng/ml) was
generally higher, especially after 48 h, but the difference
in apoptosis between the two cell suspension matrices on
day 2 was not significant.
The availability of 8-MOP influences binding to DNA
and, thus, the induction of T-cell apoptosis. Therefore,
residual 8-MOP concentrations were analyzed by 8-MOP
starting concentration and type of cell suspension matrix
(see Table 2). At the lower starting concentration
(200 ng/ml), residual 8-MOP was 119–215 ng/ml (median
168 ng/ml) in plasma and 149–203 ng/ml (median
162 ng/ml) in NaCl. The higher starting concentration
led to a residual 8-MOP of 269–325 ng/ml in plasma
(median 290 ng/ml) and 197–276 ng/ml in NaCl (median
266 ng/ml). With high-dose 8-MOP, there was no signifi-
cant difference in residual 8-MOP between plasma and
NaCl. The patients were treated on two consecutive days
per treatment cycle. No remaining 8-MOP was detectable
in the pre-sample on the second treatment day, con-
firming that 8-MOP is excreted within less than 24 h.
With regards to the two UVA irradiation devices, less
FIGURE 5 T-cell apoptosis induction rates by cell suspension matrix and 8-MOP starting concentration. Dead (Annexin V+7-AAD+)
and apoptotic (Annexin V+ 7-AAD) T-cell ratio (post/pre as a percentage) detected 24 and 48 h following extracorporeal photopheresis
with 8-MOP concentrations of 200 ng/ml (n = 30; UVA PIT and Macogenic G2) and 340 ng/ml (n = 12; UVA PIT) in plasma or in saline
(0.9% NaCl). Asterisks (*) denote significance (p < 0.05). UVA, ultraviolet light A
TABLE 2 Residual 8-methoxypsoralen after ultraviolet light A
(UVA) irradiation
200 ng/ml 8-MOP 340 ng/ml 8-MOP
Plasma NaCl Plasma NaCl
Min 119 149 269 197
Max 215 203 325 276
Median 168 162 290 266
Note: Residual 8-MOP concentrations in extracorporeal photopheresis
products were determined after UVA irradiation for samples pre-incubated
with an 8-MOP starting concentration of 200 ng/ml versus 340 ng/ml and
with plasma versus physiological saline solution (0.9% NaCl) as the cell
suspension matrix.
6 HÄHNEL ET AL.
8-MOP remained in solution after UVA treatment with
UVA PIT compared with Macogenic G2, but the differ-
ence was not statistically significant.
Considering the total amount of photoactive 8-MOP
transfused with the photopheresis product, there was
24–60 μg (median 34 μg) in plasma and 29–57 μg (median
45 μg) in NaCl after an initial dose of 200 ng/ml, and
53–64 μg (median 57 μg) in plasma and 39–55 μg (median
53 μg) in NaCl after an initial dose of 340 ng/ml.
Some research groups have defined 8-MOP dosage
recommendations to achieve inactivation of lympho-
cytes, but not of monocytes by multiplying the concen-
tration of photosensitizer with applied UV dose.33, 34
The resulting effective dose is approximately 50–400 ng
8-MOPJ/mlcm2. In the present study, ECP with UVA
PIT resulted in values of 268–422 ng 8-MOPJ/mlcm2
(median: 315 ng 8-MOPJ/mlcm2), whereas ECP with
Macogenic G2 yielded values of 318–430 ng
8-MOPJ/mlcm2 (median: 363 ng 8-MOPJ/mlcm2), in
both cases, with plasma as the suspension matrix and
with 200 ng/ml as the initial 8-MOP concentration.
4 | DISCUSSION
ECP patients benefit from its immune suppressive and
immune regulatory effects. One of the main mechanisms
of ECP is lymphocyte apoptosis.9, 10 The present study
elucidated critical parameters that affect the efficacy of
this procedure. Increasing the starting concentration
of 8-MOP from 200 to 340 ng/ml in combination with
replacing plasma with saline as the cell suspension
matrix had a major influence on the availability of the
drug in solution, as reflected by a significant increase of
T-cell apoptosis.
Besides determining cellular composition, hematocrit,
and residual 8-MOP, we analyzed T-cell apoptosis as a func-
tional measure. Whereas these tests revealed no direct rela-
tionship between cell composition and lymphocyte
apoptosis, the hematocrit should be kept lower than 4% to
avoid interference with the UVA irradiation.35 For treat-
ment optimization purposes, we varied the cell suspension
matrix as well as the starting concentration of the photosen-
sitizer 8-methoxypsoralen. UVA irradiation was done on
one of two different devices, which act by agitation
(Macogenic G2) or circulation of the cell suspensions (UVA
PIT system). In Europe, offline photopheresis products are
mainly regulated as Advanced Therapy Medicinal Products
(ATMP) and are subject to pharmaceutical authority con-
trol. Photopheresis with UVA PIT can be performed as
inline ECP, that is, with a continuous connection between
the ECP system and the patient. Therefore, all procedures
with the higher 8-MOP starting concentration were per-
formed with the UVA PIT system. Our analyses revealed no
significant difference in apoptosis induction rates between
the two devices. Both systems use a different composition of
container sets and plastic materials, for which the
photoactive substance 8-MOP is already known to have an
affinity.22 Although 8-MOP adhesion and absorption to
plastic is more prominent with saline (about 60%) than
plasma (about 10%), our data revealed no significant differ-
ence in residual 8-MOP between the two cell suspension
matrices. However, these data may not reflect a poten-
tial difference in availability of 8-MOP for the uptake
into the cells. Although plasma is associated with
lower absorption of 8-MOP to plastic containers, it
facilitates plasma protein binding of the photosensi-
tizer (80%–90%), resulting in reduced availability of
8-MOP for DNA intercalation.21, 23, 36 In the present
study, this was reflected by significantly lower lympho-
cyte apoptosis induction rates in plasma than in saline.
Increasing the concentration of 8-MOP to 340 ng/ml,
the dose typically used for inline ECP, resulted in a clear
increase of apoptosis induction of cells suspended in
plasma as well as in saline after 24 h, and a further
increase after 48 h. Apoptosis induction at 48 h was not
significantly higher with saline compared with plasma
(p > .05). This is in accordance with Laulhé et al., who
stated that plasma reduced apoptosis induced by photo-
pheresis.20 Concerning the potential toxicity of 8-MOP,
the total maximum dose in the ECP product was 64 μg
8-MOP, which is not harmful for the patient. 8-MOP is
used orally for the treatment of psoriasis at a dose of
70–160 mg per day,37 which is 1000-fold higher than the
dose in ECP.33
In addition, our analysis of lymphocyte apoptosis and
caspase activity 24 and 48 h after ECP indicated that cells
suspended in plasma and treated with a starting dose of
200 ng/ml 8-MOP have suitable characteristics for suc-
cessful treatment. However, increasing the starting con-
centration of 8-MOP to 340 ng/ml, the level used for
inline ECP, resulted in a further increase of lymphocyte
apoptosis. Suspending the cells in physiological saline
instead of plasma also resulted in a significant increase of
T-cell apoptosis. The latter finding suggests that the total
amount of free 8-MOP in saline solution is higher despite
increased adhesion to plastic.
The therapeutic action of ECP relies on apoptosis.4, 15–19
The concept is that more apoptosis would translate to
higher efficacies. However, ECP relies also on cell
interactions. This involves the activation of monocytes
by platelets, which adhere to fibrinogen that is depos-
ited on plastic surfaces of the device sets.11 Replacing
plasma with saline is supposed to not affect these cell
interactions because of two reasons: (1) shear is a fac-
tor in the activation of platelets, and (2) mononuclear
cells were collected in a defined volume of plasma
followed by supplementing the suspension with saline.
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Thus, all components for the effect of monocyte and
platelet interaction were present in all groups. With
regard to lymphocyte apoptosis as an important effect
of ECP, improving the process conditions would be
beneficial for binding of the photosensitizer to DNA
and thus for apoptosis induction. However, the effect
of such an increase in lymphocyte apoptosis on the
clinical effect and patient recovery needs to be clarified
in further studies.
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